CN107603971A - 一种原位杂交探针的制备方法 - Google Patents
一种原位杂交探针的制备方法 Download PDFInfo
- Publication number
- CN107603971A CN107603971A CN201711000583.8A CN201711000583A CN107603971A CN 107603971 A CN107603971 A CN 107603971A CN 201711000583 A CN201711000583 A CN 201711000583A CN 107603971 A CN107603971 A CN 107603971A
- Authority
- CN
- China
- Prior art keywords
- dna
- label
- situ hybridization
- hybridization probe
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000523 sample Substances 0.000 title claims abstract description 93
- 238000007901 in situ hybridization Methods 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000012634 fragment Substances 0.000 claims abstract description 27
- 108091008146 restriction endonucleases Proteins 0.000 claims abstract description 24
- 230000003321 amplification Effects 0.000 claims abstract description 16
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 16
- 238000010348 incorporation Methods 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 230000009144 enzymatic modification Effects 0.000 claims abstract description 10
- 238000013519 translation Methods 0.000 claims abstract description 10
- 239000000758 substrate Substances 0.000 claims abstract description 9
- 230000037452 priming Effects 0.000 claims abstract description 6
- 230000029087 digestion Effects 0.000 claims description 27
- 238000009396 hybridization Methods 0.000 claims description 22
- 238000000746 purification Methods 0.000 claims description 12
- 238000013467 fragmentation Methods 0.000 claims description 11
- 238000006062 fragmentation reaction Methods 0.000 claims description 11
- 238000011084 recovery Methods 0.000 claims description 11
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 9
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 238000006073 displacement reaction Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 238000011901 isothermal amplification Methods 0.000 claims description 2
- 230000009257 reactivity Effects 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 30
- 108020004414 DNA Proteins 0.000 description 107
- 210000000349 chromosome Anatomy 0.000 description 28
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 18
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 18
- 238000012360 testing method Methods 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 230000002068 genetic effect Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000013461 design Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 6
- LGZXYFMMLRYXLK-UHFFFAOYSA-N mercury(2+);sulfide Chemical compound [S-2].[Hg+2] LGZXYFMMLRYXLK-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108020003215 DNA Probes Proteins 0.000 description 5
- 239000003298 DNA probe Substances 0.000 description 5
- 108010042407 Endonucleases Proteins 0.000 description 5
- 102000004533 Endonucleases Human genes 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 230000002559 cytogenic effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- -1 aliphatic primary amine Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000002230 centromere Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010076804 DNA Restriction Enzymes Proteins 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000576133 Alphasatellites Species 0.000 description 1
- 108091029845 Aminoallyl nucleotide Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 238000007397 LAMP assay Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 108020004487 Satellite DNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000009432 framing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000985 reactive dye Substances 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种原位杂交探针的制备方法。方法为,将目标DNA片段化,回收150‑600bp的片段,经过酶修饰处理,与含有限制性内切酶位点序列的DNA衔接子间隔连接成DNA大环和长链;A或B进行大量DNA的获得和标记:A等温扩增,扩增时加入带有标记物的单核苷酸底物,得到带有标记物的DNA产物;或B等温扩增,所得产物以缺口平移法或随机引物法掺入带有标记物的单核苷酸底物,得到带有标记物的DNA产物;对所得带有标记物的DNA产物用对应的限制性内切酶进行消化,即得到长度为150‑600bp的原位杂交探针。本发明所述方法准确地控制了探针的长度范围,降低了生产成本,提高了产品质量。
Description
技术领域
本发明涉及生物技术DNA探针领域,尤其涉及一种原位杂交探针的制备方法。
背景技术
DNA杂交是依据碱基互补原理,以带有标记物的DNA片段(即为DNA探针),与具有相同碱基序列的DNA(即靶序列)两者变性成单链后在复性的过程中互相结合形成双链的过程(即DNA杂交)。通过对探针上标记物的检测,用于靶序列的定性和定量测量。探针通常处于溶液中为流动相,而靶序列通常处于固定相。依据靶序列所处的状态和载体不同,如DNA在膜上的杂交称为Southern杂交,DNA在芯片上的比较基因组杂交(CGH),在细胞滴片和组织切片上的原位杂交,染色体或细胞在溶液中或微流控系统中的杂交等。在商业运用上,需要大量地制备DNA探针,下面以原位杂交探针为例进行说明。
原位杂交技术(In-Situ Hybridization简称ISH)和荧光原位杂交技术(Florescence In-Situ Hybridization简称FISH);原位杂交技术是以带有标记物的DNA小片段,即杂交探针,与组织或细胞内的DNA同源靶序列进行杂交,通过检测标记物所产生的信号,来检测标本中DNA(或基因)或染色体数目或位置变化的一种分子细胞遗传学技术。原位杂交探针即是带有标记物的核苷酸序列(小片段DNA),对于其长度有较严格的要求,太长不易穿透到达靶序列所在位置,太短则特异性不足而产生非特异信号或高背景。荧光原位杂交(FISH)是以荧光标记的DNA探针与组织或细胞内的DNA同源序列进行杂交,通过在荧光显微镜下观察和计数各种荧光信号的数量和分布来记录和分析结果。它将荧光信号的高灵敏度、直观性和原位杂交在细胞和组织内的定位结合起来,从而对染色体或基因异常的细胞、组织样本进行检测和诊断,为各种基因相关疾病的分型和预后提供准确的依据,显示出与一些传统技术相比的明显优势。(1.Raap AK:Advances in fluorescence in situhybridization.Mutat Res 400:287–298(1998).2.Raap AK:Overview of fluorescencein situ hybridization techniques for molecular cytogenetics.Curr Protoc CytomChapter 8:Unit 8.1(2001).3.Wang N:Methodologies in cancer cytogenetics andmolecular cytogenetics.Am J Med Genet.115:118–124(2002).4.Wolff DJ,Bagg A,Cooley LD,Dewald GW,Hirsch BA,et al:Guidance for fluorescence in situhybridization testing in hematologic disorders.J Mol Diagn 9:134–143(2007))。
目前临床检测基因扩增、基因缺失、染色体异位的原位杂交探针一般是以大量的BAC DNA为模板制备而来,使用的标记方法大多为缺口平移法或随机引物法(例如,发明名称为:乳腺癌分子标志物相关探针的制备方法及其应用,申请号:201010284090.3中山大学达安基因股份有限公司;发明名称为:用于检测前列腺癌的检测剂及其用途,申请号201010113005.7,北京金菩嘉医疗科技有限公司)。采用这两种方法制备探针都需要制备大量的BAC DNA,成本较高,标记方法不易准确控制探针的长度范围,导致不同批次生产的产品变化较大(重复性不好),产品性能指标不稳定。
发明内容
本发明的目的在于提供一种解决现有方法大规模制备原位杂交探针成本较高,探针长度范围不易控制而致产品质量不稳定的问题,而提供了一种DNA原位杂交探针的制备方法。
为实现上述目的,本发明提供一种DNA原位杂交探针的制备方法,其特征在于,包括以下步骤,
目标DNA的片段化和选择性回收:将目标DNA片段化,选择性回收150-600bp的小片段;
酶修饰处理:对150-600bp的小片段DNA的两端进行酶修饰处理,使两端成平末端、5'端加磷酸和3'端加dA;
连接成大环和长链:将上述处理后的小片段DNA与含有限制性内切酶位点序列的DNA衔接子间隔连接成DNA大环和长链;所述含有限制性内切酶位点序列的DNA衔接子的5'端加了磷酸和3'端加了dT;
大量DNA的获得和标记:
A,等温扩增,扩增时加入带有标记物的底物,得到带有标记的DNA产物;
或B,等温扩增,所得扩增产物以缺口平移法或随机引物法掺入带有标记物的单核苷酸底物,得到带有标记物的DNA产物;
所述的标记物包括直接标记物和间接标记物,直接标记物为能够被检测系统检测到的标记物,包括但不限于放射性同位素、生物素、抗原或半抗原如地高辛、荧光素;间接标记物为某些化学基团,不能够被检测系统检测到,这些化学基团包括但不限于脂肪族伯胺基(aliphatic primary amine group)、硫醇(thiols),需要经过与带有对应反应基团的直接标记物(通过反应基团)进行偶联,比如胺基(aa,aminoallyl)与琥珀酰亚胺酯(SE,succinimidyl ester)在碱性条件下发生反应而连接,而将直接标记物标记上去。
酶切:采用与上述DNA衔接子上碱基序列对应的DNA限制性内切酶消化带有标记物的DNA产物,酶切产物长度范围150-600bp;
得到探针:
若所述带有标记物的DNA产物中的标记物为直接标记物,则所得到的酶切产物即为原位杂交探针;
若所述带有标记物的DNA产物中的标记物为间接标记物,则所得到的酶切产物经过与具有反应活性的直接标记物进行偶联,从而得到原位杂交探针。
进一步,所述得到的原位杂交探针进一步纯化,定量。
进一步,所述目标DNA为纯化后的目标DNA。
进一步,所述A或B步骤中,等温扩增时所用的引物为含有限制性内切酶位点的衔接子序列的寡核苷酸或随机序列寡核苷酸。
进一步,所述A或B步骤中,等温扩增所用的酶为具有链置换活性的DNA多聚酶。
进一步,所述等温扩增所用的酶为Phi29DNA多聚酶、Bst DNA多聚酶大片段。
进一步,所述A或B步骤中,所述标记物为直接标记物或间接标记物。
所述目标DNA即包含探针靶序列的DNA。
本发明插入的衔接子上的酶切位点序列:插入序列以不影响酶切掺入标记物的DNA为原则,例如掺入带有标记物的dUTP,T被U替代后内切酶不能切割,则不应选择含有T和A的序列;以插入的酶切位点序列在靶序列中尽量稀少为原则,减少对探针产品设计长度范围的影响。
本发明采用具有链置换活性的DNA多聚酶(如Phi29DNA多聚酶、Bst DNA多聚酶大片段),是高效的DNA多聚酶,具有特殊的链置换和连续合成特性,并且在恒温下工作,常应用于微量DNA的大量扩增,比如单细胞全基因组测序样本的制备。
本发明包含以下有益效果:
本发明以小量的目标DNA为起始物,将其制成设计长度范围内的小片段文库,与含有限制性内切酶位点序列的DNA衔接子(adaptor)互相间隔连接成DNA大环和长链模板,通过恒温滚环扩增(Loop mediated isothermal amplification,LAMP)(针对环状DNA)和恒温多点置换扩增(Multiple displacement amplification,MDA)(针对线性DNA)进行大量扩增,在扩增的同时掺入标记物或随后以缺口平移法(或随机引物法及其变种)掺入标记物,再以限制性内切酶将标记了的DNA切开还原成原来文库片段长度的小片段,即得到大量的设计长度范围的探针。与通常直接以BAC、质粒或PCR产物等为模板采用缺口平移法或随机引物法标记制备探针的技术比较,本发明通过将设计长度的探针文库片段以酶切位点序列间隔连接成大环和长链DNA为探针模板,以插入的酶切位点序列(或随机序列)为引物序列,进行DNA等温扩增,在扩增的同时或之后采用其他方法掺入带有标记物的底物标记DNA,插入的酶切位点是将标记DNA切割成设计长度范围的探针的切割位点,提供了更为方便地大量生产设计长度范围探针的制备方法,增加了产量,准确地控制了探针的长度范围,降低了生产过程中原材料的消耗,节省成本,提高了产品的性能指标。
采用本发明的方法制备的原位杂交探针可用于但不限于(细胞片或组织切片上的)间期或中期细胞核的原位杂交或CGH芯片杂交,对杂交结果的分析能了解特定基因或DNA片段在特定细胞/细胞群/组织/植物/动物/人体中的存在与否、数目变化、位置变化,与疾病的早期发现,诊断,选择治疗用药,或判断预后相关。
附图说明
图1为实施例2的HER2基因检测FISH探针的琼脂糖凝胶电泳图;
图2为实施例2的HER2基因检测FISH探针和实施例1的CEN17在正常人中期细胞染色体上的FISH实验结果图;
图3为实施例2的HER2基因检测FISH探针和实施例1的CEN17在正常人间期细胞上的FISH实验结果图。
图4为实施例3的13号染色体特异性FISH探针在正常人中期细胞染色体上的FISH实验结果图。
具体实施方式
下面详细描述本发明的实施例,所述实施例的示例在附图中示出,其中自始至终相同或类似的标号表示相同或类似的元件或具有相同或类似功能的元件。下面通过参考附图描述的实施例是示例性的,旨在用于解释本发明,而不能理解为对本发明的限制。实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规产品。
本发明的第一种原位杂交探针的制备方法:
一、将纯化了的目标DNA片段化处理成长度为300bp左右的小片段;
二、回收150-600bp长度范围的小片段DNA;
三、对步骤二回收的小片段DNA两端进行酶修饰处理,使两端成平末端、5'端加磷酸和3'端加dA;
四、在DNA连接酶的作用下,将步骤三酶修饰处理后的小片段DNA与含有限制性内切酶位点序列的5'端加磷酸和3'端加dT的DNA衔接子间隔连接成DNA大环和长链;
五、采用衔接子序列的寡核苷酸为引物,将步骤四所得的DNA大环和长链进行等温滚环(LAMP)和多点置换扩增(MDA),同时掺入带有标记物的脱氧核苷酸,如dUTP-荧光素或aa-dUTP;得到扩增后带有标记物的DNA;
六、对上述所得扩增后带有标记物的DNA进行酶切,采用与插入的衔接子序列对应的限制性内切酶,得到长度为150-600bp的酶切产物;
七、对上述所得酶切产物进行纯化、定量,所得即为探针,完成DNA杂交探针的制备。
步骤一中所述的目标DNA是双链DNA,可以是线性或环状,可以是超螺旋状态,可以是连续的也可以是有缺口的,来源包括但不限于质粒、BAC、YAC、PCR产物、RT-PCR产物、DNA酶切产物或连接产物、人工扩增产物、人工合成产物;
所述的连接满足DNA衔接子上3’末端的dT与小片段DNA 3’末端的dA互补;
步骤五中如果掺入的标记物为间接标记物aa,则还需要在步骤六和七之间增加一个偶联步骤,将直接标记物标记上去。
本发明的第二种原位杂交探针的制备方法,其中除上述步骤五所述的引物为随机引物外,其他均相同。
本发明的第三种原位杂交探针的制备方法,与上述两种方法的不同点在于以下步骤,其他步骤均相同:
步骤五、进行等温扩增时不掺入带有标记物的脱氧核苷酸;
步骤六、将步骤五得到的DNA,以缺口平移法掺入带有标记物的单核苷酸底物,对DNA进行标记;
步骤七、采用与衔接子上酶切位点对应的限制性内切酶消化标记了的DNA产物,得到长度为150-600bp的酶切产物;
步骤八、对上述所得酶切产物进行纯化、定量,所得即为探针,完成DNA原位杂交探针的制备。
本发明的第四种原位杂交探针的制备方法,与第三种原位杂交探针的制备方法的不同点在于以下步骤,其他步骤均相同:
步骤六、将步骤五得到的DNA,以随机引物法掺入带有标记物的单核苷酸底物,对DNA进行标记;
本发明的第五种原位杂交探针的制备方法,与第四种原位杂交探针的制备方法的不同点在于以下步骤,其他步骤均相同:
步骤六、将步骤五得到的DNA,采用衔接子序列的寡核苷酸为引物替代随机引物,对DNA进行标记;
实施例1:人17号染色体计数FISH探针(CEN17)的制备
一、以正常人基因组DNA(可以采购得到)为模板,按照PETER E.WARwRToN,StGILLIAN M.GREIG,THOMAS HAAF,AND HUNTINGTON F.WILLARD.PCR Amplification ofChromosome-Specific Alpha Satellite DNA:Definition of Centromeric STS Markersand Polymorphic Analysis.GENOMICS 11,324-333(1991)里描述的方法得到0.85kb的17号染色体着丝粒α卫星重复序列片段PCR产物。
采用QIAquick PCR Purification Kit纯化PCR产物。
二、取1μg的以上步骤获得的DNA,以聚焦超声波法进行破碎至300bp左右的长度,通过2%的琼脂糖凝胶电泳,以100bp DNA ladder为参照,切割回收150-600bp长度范围内的DNA片段;采用Qiagen公司的凝胶提取试剂盒(QIAquick Gel Extraction Kit)回收片段;
三、酶修饰处理:采用New England Biolabs公司的Ultra End Repair/dA-Tailing Module,按照说明书的操作步骤将步骤二回收的DNA片段末端修齐,将其5’端磷酸化,并在3’端加dA,然后采用Qiagen公司的PCR纯化试剂盒(QIAquick PCRPurification Kit)对修饰后的DNA片段进行回收;
四、连接成大环和长链:将上述所得含有DNA限制性内切酶SacII位点序列的衔接子(adaptor)与步骤三回收的修饰后的DNA片段连接;
衔接子(adaptor)为双链,其5’端均磷酸化。序列如下所示:
5’-pCCGCGGT-3'
3’-TGGCGCCp-5' SEQ ID NO:1。
衔接子(adaptor)连接的具体操作步骤如下:
采用如下连接体系,将微离心管置于冰上,加入如下50μl的反应液(可以按比例扩大反应体积),用加样器轻柔地上下吹打混合,短暂离心,然后置于16℃条件下过夜。
采用Qiagen公司的QIAamp DNA Blood Kits,对连接后的产物进行纯化回收,去除未连接的衔接子(adaptor),测定OD值,获得大环和长链DNA探针模板;
五、大量标记DNA的获得:将步骤四得到的探针模板DNA大量扩增,同时掺入标记物dUTP-FITC(fluorescein isothiocyanate)(也可以是间接标记物aa-dUTP,如此,则需要在第六步之后增加一步与FITC SE的偶联反应,具体参见后述实施例),以插入的序列CCGCGGT(SEQ ID NO:2,即SEQ ID NO:1的单链)为引物,反应体系及过程如下(可以按比例增加反应体积):
先96℃,2分钟,再室温10分钟,然后置于冰上,再加入下列成分,终体积50μl,混匀;
然后,先60℃,6小时,再80℃,15分钟。
采用Qiagen公司的QIAamp DNA Blood Kits对产物进行纯化回收,测定OD值。
六、酶切:以限制性内切酶SacII将步骤五所得进行酶切,得到长度为150-600bp的酶切产物。
酶切反应体系为(可以按比例增加或减少反应体积):
步骤五所得 100μg
Sac II 1000u(单位)
去离子水 使达到1000μl
将上述酶切反应体系置于37℃持续16小时;
七、采用Qiagen公司的PCR纯化试剂盒(QIAquick PCR Purification Kit)纯化酶切产物,测定OD值,获得绿色荧光素FITC标记的17号染色体计数FISH探针(记为CEN17)。
实施例2:人类表皮生长因子受体2(HER2)基因检测FISH探针的制备
与以上实施例1不同的是DNA来源于BAC,扩增和标记分开进行,扩增时采用6个碱基的随机引物(包含在试剂盒中),扩增后采用缺口平移法掺入标记物,掺入的标记物为直接标记物或间接标记物。
一、根据HER2基因在染色体上的位置,自ThermoFisher Scientific公司购买细菌人工染色体(Bacterial Artificial Chromosome,BAC)克隆:RP11-909L6,其中含有HER2基因及其左右的染色体DNA,长度约为185kb;
采用末端测序方法测定BAC克隆插入片段两末端数百个碱基的序列,与NCBI发表的已知序列进行对比核实,正确的进行下一步实验;
二、取1μg BAC DNA,以聚焦超声波法进行片段化处理并回收150-600bp的DNA片段,方法同实施例1;
三、酶修饰处理:方法同实施例1;
四、将含有DNA限制性内切酶SmaI位点序列的衔接子(adaptor)与步骤四回收的DNA片段连接;
衔接子(adaptor)为双链,其5’端均磷酸化。序列如下所示:
5’-pCCCGGGT-3'
3’-TGGGCCCp-5' SEQ ID NO:3;
与衔接子(adaptor)连接:方法同实施例1:
五、大量DNA的获得:以步骤四得到的DNA为模板大量扩增,采用Qiagen公司的REPLI-g Single Cell Kit试剂盒(其原理为LAMP和MDA,,采用Phi29DNA多聚酶,以随机序列的六个碱基寡核苷酸为引物),按照说明书操作,采用Qiagen公司的QIAamp DNA BloodKits对扩增产物进行纯化回收;
六、DNA的标记:以步骤五获得的扩增产物为模板,以缺口平移法掺入直接标记物dUTP-TAMRA(carboxytetramethylrhodamine)或间接标记物aa-dUTP,方法如下:
将上述混合物置于30℃持续16小时;
采用Qiagen公司的QIAamp DNA Blood Kits对扩增产物进行纯化回收,测定OD值。
七、酶切:以限制性内切酶SmaI将步骤六所得DNA进行酶切,得到长度为150-600bp的酶切产物;
酶切反应体系为:
DNA 100μg
SmaI 1000u(单位)
去离子水 使达到1000μl
将上述酶切反应体系置于37℃持续16小时;
八、采用Qiagen公司的PCR纯化试剂盒纯化步骤七的酶切产物,测定OD值,
如果步骤六掺入的是直接标记物,则获得橘红色荧光TAMRA标记的HER2探针;如果步骤六掺入的是间接标记物,则:
九、DNA中掺入的aa与TAMRA SE的偶联,参照以下文献或者产品说明书(反应体积可以按比例相应扩大):
W.Gregory Cox and Victoria L.Singer.Fluorescent DNA hybridizationprobe preparation using amine modification and reactive dyecoupling.BioTechniques 36:114-122(January 2004)
十、产物经乙醇沉淀法纯化后测定OD值,获得橘红色荧光素TAMRA标记的HER2探针。
关于实施例2的说明:缺口平移标记法的特点是快速、简便、标记的探针均匀、特异性高,探针标记率比Bst DNA多聚酶掺入标记的探针标记率高;间接标记比直接标记节省成本。
实施例3:人13号染色体特异FISH探针
与以上实施例1和例2不同的是:目标DNA来源于整条染色体,采用随机引物,等温扩增和标记同时进行,掺入的标记物为间接标记物。
一、采购或自备(方法略)正常人外周血中期淋巴细胞滴片;
二、采用细胞遗传学染色体显带技术,在显微镜下辨别和编号染色体,从玻片上刮取和收集十条完整的13号染色体;
三、大量DNA的获得:以步骤二得到的染色体为DNA来源,采用Qiagen公司的REPLI-g Single Cell Kit试剂盒进行DNA大量扩增,按照说明书操作,采用Qiagen公司的QIAampDNA Blood Kits对扩增产物进行纯化回收;
四、取1μg以上步骤获得的DNA,以聚焦超声波法进行破碎并回收150-600bp的DNA片段,方法同实施例1;
五、酶修饰处理:方法同实施例1;
六、将含有DNA限制性内切酶位点序列的衔接子(adaptor)与步骤五修饰后回收的DNA片段连接获得DNA探针模板,方法同实施例1;
七、大量标记DNA的获得:以步骤六得到的DNA为模板大量等温扩增,同时掺入间接标记物aa-dUTP,
扩增时采用6个碱基的随机寡核苷酸(序列为NNNNNN,SEQ ID NO:4,其中N表示A或T或G或C)为引物,反应体系及过程如下(可以按比例增加反应体积):
先96℃,2分钟,再室温10分钟,然后置于冰上,再加入下列成分,终体积50μl,混匀;
然后,先60℃,6小时,再80℃,15分钟。
采用Qiagen公司的QIAamp DNA Blood Kits对产物进行纯化回收,测定OD值。
八、以限制性内切酶将步骤七所得进行酶切,得到150-600bp的片段,方法同实施例1;
九、采用Qiagen公司的PCR纯化试剂盒(QIAquick PCR Purification Kit)纯化酶切产物,测定OD值,
十、DNA中掺入的aa与TAMRA SE的偶联,方法同实施例2;
十一、产物经乙醇沉淀法纯化后测定OD值,获得橘红色荧光素TAMRA标记的13号染色体特异性FISH探针。
实施例4:效果验证实验
将所述实施例2所得橘红色荧光素TAMRA标记的HER2基因检测FISH探针进行琼脂糖凝胶电泳,结果见图1,图1为所得HER2探针的琼脂糖凝胶电泳图,其中泳道1为100bp DNAladder,泳道2为探针,显示探针长度在150-600bp的设计范围,达到设计要求。
配制HER2基因检测FISH探针杂交液
每10μl HER2基因检测FISH探针杂交液的成分如下:实施例2所得橘红色荧光素TAMRA标记的HER2基因检测FISH探针20ng,实施例1所得17号染色体计数探针CEN1710ng,人COT-1DNA(购自ThermoFisher Scientific)1μg,50%体积比的去离子甲酰胺,2XSSC,10%重量体积比的硫酸葡聚糖。
配制13号染色体特异性FISH探针杂交液
每10μl 13号染色体特异性FISH探针杂交液的成分如下:实施例3所得橘红色荧光素TAMRA标记的13号染色体特异性FISH探针20ng,人COT-1DNA(购自ThermoFisherScientific)1μg,50%体积比的去离子甲酰胺,2XSSC,10%重量体积比的硫酸葡聚糖。
原位杂交:
采用细胞悬液,常规制作染色体玻片标本,玻片过梯度乙醇依次脱水,晾干;常规胃蛋白酶消化,将10μl上述HER2基因检测FISH探针杂交液或13号染色体特异性FISH探针杂交液加于玻片杂交区域,盖上盖玻片,以橡胶水封片,78℃变性5分钟,封片后置于湿盒中,37℃杂交过夜。再按照如下顺序洗片:4×SSC溶液中,振荡漂洗5分钟;2×SSC,0.1%体积比的Tween-20溶液中,振荡漂洗4×2.5分钟;0.1×SSC溶液中,振荡漂洗5分钟;在梯度乙醇中依次脱水,晾干。将20μl DAPI复染剂滴加于杂交区域位置,立即盖上盖玻片。在荧光显微镜下选用合适的滤光片观察和照相记录结果。
试验结果数据见图2、3和4所示。图2为HER2基因检测FISH探针杂交液在体外培养的正常人中期细胞(来源于正常人外周血单核细胞)染色体上的FISH实验结果图;其中,1为HER2基因检测FISH探针产生的信号,2为17号染色体计数原位杂交探针CEN17产生的信号。
图3为HER2基因检测FISH探针杂交液在体外培养的正常人间期细胞(来源于正常人外周血单核细胞)上的FISH实验结果图;其中,1所指为HER2基因检测FISH探针产生的信号,2所指为17号染色体计数原位杂交探针CEN17产生的信号。
从图2和图3可以看出,CEN17信号定位于17号染色体的着丝粒上,HER2信号位于17号染色体长臂近着丝粒处(1区2带,17q12),在正常的细胞中各有2个信号,达到设计要求和预期目的。
图4为13号染色体特异性FISH探针杂交液在体外培养的正常人中期细胞(来源于正常人外周血单核细胞)染色体上的FISH实验结果图,一对13号染色体整体显示荧光信号,达到设计要求和预期目的。
尽管上面已经示出和描述了本发明的实施例,可以理解的是,上述实施例是示例性的,不能理解为对本发明的限制,也不能理解为对依据本发明而获得探针产物的应用范围的限制,本领域的普通技术人员在不脱离本发明的原理和宗旨的情况下在本发明的范围内可以对上述实施例进行变化、修改、替换和变型。
Claims (7)
1.一种原位杂交探针的制备方法,其特征在于,包括以下步骤,
目标DNA的片段化和选择性回收:将目标DNA片段化,选择性回收150-600bp的小片段;
酶修饰处理:对150-600bp的小片段的两端进行酶修饰处理,使两端成平末端、5'端加磷酸和3'端加dA;
连接成大环和长链:将上述处理后的小片段与含有限制性内切酶位点序列的DNA衔接子间隔连接成DNA大环和长链;所述含有限制性内切酶位点序列的DNA衔接子的5'端加了磷酸和3'端加了dT;
大量DNA的获得和标记:
A,等温扩增,扩增时掺入带有标记物的单核苷酸底物,得到带有标记物的DNA产物;
或B,等温扩增,所得扩增产物以缺口平移法或随机引物法掺入带有标记物的单核苷酸底物,得到带有标记物的DNA产物;
酶切:采用与上述DNA衔接子上碱基序列对应的DNA限制性内切酶消化带有标记物的DNA产物,酶切产物长度范围150-600bp;
得到探针:
若所述带有标记物的DNA产物中的标记物为直接标记物,则所得到的酶切产物即为原位杂交探针;
若所述带有标记物的DNA产物中的标记物为间接标记物,则所得到的酶切产物经过与具有反应活性的直接标记物进行偶联,从而得到原位杂交探针。
2.根据权利要求1所述原位杂交探针的制备方法,其特征在于,所述得到的原位杂交探针进一步纯化,定量。
3.根据权利要求1所述原位杂交探针的制备方法,其特征在于,所述目标DNA为纯化后的目标DNA。
4.根据权利要求1所述原位杂交探针的制备方法,其特征在于,所述A或B步骤中,等温扩增时所用的引物为含有限制性内切酶位点的衔接子序列的寡核苷酸或随机序列寡核苷酸。
5.根据权利要求1所述原位杂交探针的制备方法,其特征在于,所述A或B步骤中,等温扩增所用的酶为具有链置换活性的DNA多聚酶。
6.根据权利要求5所述原位杂交探针的制备方法,其特征在于,所述等温扩增所用的酶为Phi29 DNA多聚酶、Bst DNA多聚酶大片段。
7.根据权利要求1所述原位杂交探针的制备方法,其特征在于,所述A或B步骤中,所述标记物为直接标记物或间接标记物。
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711000583.8A CN107603971B (zh) | 2017-10-24 | 2017-10-24 | 一种原位杂交探针的制备方法 |
| PCT/CN2018/099530 WO2019080595A1 (zh) | 2017-10-24 | 2018-08-09 | 一种原位杂交探针的制备方法 |
| EP18871629.4A EP3702455B1 (en) | 2017-10-24 | 2018-08-09 | Preparation method for in situ hybridisation probe |
| US16/758,283 US11359193B2 (en) | 2017-10-24 | 2018-08-09 | Preparation method for in-situ hybridization probe |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711000583.8A CN107603971B (zh) | 2017-10-24 | 2017-10-24 | 一种原位杂交探针的制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107603971A true CN107603971A (zh) | 2018-01-19 |
| CN107603971B CN107603971B (zh) | 2020-02-04 |
Family
ID=61079631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711000583.8A Active CN107603971B (zh) | 2017-10-24 | 2017-10-24 | 一种原位杂交探针的制备方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11359193B2 (zh) |
| EP (1) | EP3702455B1 (zh) |
| CN (1) | CN107603971B (zh) |
| WO (1) | WO2019080595A1 (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019080595A1 (zh) * | 2017-10-24 | 2019-05-02 | 厦门龙进生物科技有限公司 | 一种原位杂交探针的制备方法 |
| CN110612351A (zh) * | 2017-03-20 | 2019-12-24 | Illumina公司 | 用于制备核酸文库的方法和组合物 |
| CN114196788A (zh) * | 2021-12-23 | 2022-03-18 | 华中农业大学 | 利用荧光原位检测技术快速检测非洲猪瘟病毒的方法 |
| CN114891787A (zh) * | 2022-05-09 | 2022-08-12 | 珠海圣美生物诊断技术有限公司 | 随机探针、制备方法及应用 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120548357A (zh) * | 2022-11-21 | 2025-08-26 | 百奥赛科生物科技有限公司 | 目标核酸序列的高通量扩增 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1384208A (zh) * | 2001-11-07 | 2002-12-11 | 哈尔滨工业大学糖业研究院 | 基因的等温滚环复制与限制性内切酶检测方法及其试剂盒 |
| CN107208091A (zh) * | 2014-11-11 | 2017-09-26 | 雅培分子公司 | 杂交探针和方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2069537B1 (en) * | 2006-09-01 | 2011-08-31 | Ventana Medical Systems, Inc. | Method for producing nucleic acid probes |
| CN107603971B (zh) * | 2017-10-24 | 2020-02-04 | 厦门龙进生物科技有限公司 | 一种原位杂交探针的制备方法 |
-
2017
- 2017-10-24 CN CN201711000583.8A patent/CN107603971B/zh active Active
-
2018
- 2018-08-09 EP EP18871629.4A patent/EP3702455B1/en active Active
- 2018-08-09 WO PCT/CN2018/099530 patent/WO2019080595A1/zh not_active Ceased
- 2018-08-09 US US16/758,283 patent/US11359193B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1384208A (zh) * | 2001-11-07 | 2002-12-11 | 哈尔滨工业大学糖业研究院 | 基因的等温滚环复制与限制性内切酶检测方法及其试剂盒 |
| CN107208091A (zh) * | 2014-11-11 | 2017-09-26 | 雅培分子公司 | 杂交探针和方法 |
Non-Patent Citations (1)
| Title |
|---|
| 李岩 等: "一种高效扩增小片段DNA方法的建立", 《首都医科大学学报》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110612351A (zh) * | 2017-03-20 | 2019-12-24 | Illumina公司 | 用于制备核酸文库的方法和组合物 |
| CN110612351B (zh) * | 2017-03-20 | 2023-08-11 | Illumina公司 | 用于制备核酸文库的方法和组合物 |
| WO2019080595A1 (zh) * | 2017-10-24 | 2019-05-02 | 厦门龙进生物科技有限公司 | 一种原位杂交探针的制备方法 |
| US11359193B2 (en) | 2017-10-24 | 2022-06-14 | Diaglogic Biolabs (Xiamen) Co., Ltd. | Preparation method for in-situ hybridization probe |
| CN114196788A (zh) * | 2021-12-23 | 2022-03-18 | 华中农业大学 | 利用荧光原位检测技术快速检测非洲猪瘟病毒的方法 |
| CN114891787A (zh) * | 2022-05-09 | 2022-08-12 | 珠海圣美生物诊断技术有限公司 | 随机探针、制备方法及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3702455A1 (en) | 2020-09-02 |
| WO2019080595A1 (zh) | 2019-05-02 |
| EP3702455A4 (en) | 2021-08-11 |
| CN107603971B (zh) | 2020-02-04 |
| US20200248170A1 (en) | 2020-08-06 |
| EP3702455B1 (en) | 2023-12-13 |
| US11359193B2 (en) | 2022-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102858995B (zh) | 靶向测序方法 | |
| CN109468384B (zh) | 一种同时检测45个y基因座的复合扩增检测试剂盒 | |
| CN107603971A (zh) | 一种原位杂交探针的制备方法 | |
| EP3050976A1 (en) | Multiplexed genomic gain and loss assays | |
| JPH03244400A (ja) | 癌評価方法 | |
| JP2006518194A5 (zh) | ||
| WO2019144582A1 (zh) | 用于检测基因突变和已知、未知基因融合类型的高通量测序靶向捕获目标区域的探针和方法 | |
| CA2409752A1 (en) | Single copy genomic hybridization probes and method of generating same | |
| WO2019062289A1 (zh) | 一种探针及其适用于高通量测序的对目标区域进行富集的方法 | |
| CN102586456B (zh) | 一种多重竞争性pcr检测拷贝数变异的方法 | |
| CN106868204A (zh) | 一种用于胃腺癌诊断的生物标志物 | |
| CN111334580A (zh) | Pik3ca基因突变检测试剂盒 | |
| JP2002533097A (ja) | ポリメラーゼヌクレオチド組み込みによる特定核酸配列の検出法 | |
| KR20190020133A (ko) | 염색체에 대한 인-시츄 혼성화를 위한 dna 탐침 | |
| CN109628573B (zh) | 一种用于无创产前检测12种染色体微缺失微重复综合征的试剂盒及其专用探针组 | |
| CN109266723A (zh) | 稀有突变检测方法、其试剂盒及应用 | |
| WO2024106109A1 (ja) | 電気泳動の移動度を改変する修飾基質を用いた遺伝子検出 | |
| CN110857451A (zh) | 一种检测复发性流产的微缺失或/和微重复的引物组合、mlpa探针、基因芯片及试剂盒 | |
| US9758815B2 (en) | Kits for characterization of chromosomal inversions using probes | |
| CN105779570B (zh) | 一种检测snp位点的方法 | |
| WO2022100766A1 (zh) | 人微卫星不稳定位点的检测方法及其应用 | |
| WO1998010073A1 (fr) | Procede et materiau de detection de champignons | |
| Hilborne et al. | Diagnostic applications of recombinant nucleic acid technology: basic techniques | |
| CN113957158B (zh) | 一种用于检测施氏鲟线粒体基因的引物探针组合物、试剂盒及其应用 | |
| CN113403406B (zh) | 一种x染色体str基因座的复合扩增体系及试剂盒 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |